EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Contemporary trends in utilization of metastasectomy in the era of targeted and immunotherapies

Jesse E Passman iD, Michael J Kallan, Jeffrey L Roberson, Sara P Ginzberg iD, Wajid Amjad, Jacqueline M Soegaard Ballester, Gabriella Tortorello iD, Douglas Fraker, Giorgos C Karakousis iD, Edmund K Bartlett iD, Heather Wachtel

Cancer · 2025

DOI: 10.1002/cncr.35664 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cancer, 2025. Verfasst von Jesse E Passman und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Surgery, Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania, USA. Hauptthemen laut MEDLINE: Metastasectomy, Immunotherapy, Melanoma, Kidney Neoplasms. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 58 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: NCI NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Metastasectomy is a useful adjunct in the management of metastatic cancer. Widespread adoption of novel targeted and immunotherapies has improved the survival profiles of multiple malignancies, which has potentially altered the role of metastasectomy. This study aimed to characterize trends in metastasectomy across five primary cancers eligible for these therapies.

Methods

The National Inpatient Sample was used to identify patients who underwent metastasectomy in the United States (2016–2021). Patients with procedure codes for resection of the lung, liver, adrenal gland, brain, or small bowel and concurrent diagnosis codes for secondary malignant neoplasm of that site were included. Subjects were subcategorized by primary malignancy: colorectal cancer, lung cancer, breast cancer, melanoma, or renal cancer. Sample weights were used to produce national estimates, which were incidence adjusted by primary malignancy. Trends in utilization were calculated with average annual percent change (AAPC) and linear regression coefficients.

Results

Colorectal cancer was the most frequent indication for metastasectomy ( n = 57,644 cases), followed by lung cancer ( n = 55,090 cases), breast cancer ( n = 12,616 cases), renal cancer ( n = 8427 cases), and melanoma ( n = 5658 cases). Utilization of metastasectomy increased over the study period for breast cancer (AAPC, +10.6%; p = .013) and melanoma (AAPC, +8.3%; p = .040) but did not change for lung cancer (AAPC, −1.6%; p = .26), colorectal cancer (AAPC, +0.3%; p = .83), or renal cancer (AAPC, +2.3%; p = .36).

Conclusions

Between 2016 and 2021, utilization of metastasectomy increased significantly for melanoma and breast cancer. The role of metastasectomy will likely continue to develop as new treatment protocols improve survival profiles for patients with metastatic disease.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

MetastasectomyImmunotherapyMelanomaKidney NeoplasmsHumansFemaleMaleMiddle AgedLung NeoplasmsColorectal NeoplasmsAgedUnited StatesBreast NeoplasmsMolecular Targeted TherapyNeoplasmsAdult

Stichwörter der Autor:innen

breast cancercolorectal cancerlung cancermelanomametastasectomyrenal cancertargeted therapies

Autor:innen und Institutionen

  • Department of Surgery, Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania, USA.
  • Leonard Davis Institute, University of Pennsylvania, Philadelphia, Pennsylvania, USA.
  • Center for Clinical Epidemiology and Biostatistics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA.
  • Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA.
  • Memorial Sloan Kettering Cancer Center, New York, New York, USA.

ORCID-Profile: Jesse E Passman, Sara P Ginzberg, Gabriella Tortorello, Giorgos C Karakousis, Edmund K Bartlett

Förderung

  • NCI NIH HHS

Zitieren

APA

Passman, J. E., Kallan, M. J., Roberson, J. L., Ginzberg, S. P., Amjad, W., Soegaard Ballester, J. M., Tortorello, G., Fraker, D., Karakousis, G. C., Bartlett, E. K., & Wachtel, H. (2025). Contemporary trends in utilization of metastasectomy in the era of targeted and immunotherapies. Cancer. https://doi.org/10.1002/cncr.35664

Vancouver

Passman JE, Kallan MJ, Roberson JL, Ginzberg SP, Amjad W, Soegaard Ballester JM, et al. Contemporary trends in utilization of metastasectomy in the era of targeted and immunotherapies. Cancer. 2025. doi:10.1002/cncr.35664

BibTeX
@article{Passman2025,
  author = {Passman, Jesse E and Kallan, Michael J and Roberson, Jeffrey L and Ginzberg, Sara P and Amjad, Wajid and Soegaard Ballester, Jacqueline M and Tortorello, Gabriella and Fraker, Douglas and Karakousis, Giorgos C and Bartlett, Edmund K and Wachtel, Heather},
  title = {Contemporary trends in utilization of metastasectomy in the era of targeted and immunotherapies},
  journal = {Cancer},
  year = {2025},
  doi = {10.1002/cncr.35664}
}
Kostenlos starten →